tbuckley/cabot-search huggingface dataset:
Synthetic Auxins in the Chemotherapy of Transplanted and Spontaneous Mouse Adenocarcinoma
Authors: C. A. Apffel, A. Tregier, F. Homburger
Journal: JNCI Journal of the National Cancer Institute (1960)

Methyl esters of certain synthetic auxins such as 2,5-dichlorophenoxyacetic acid and 2,3,4,5-tetrachlorophenoxyacetic acid, as well as the related compound, 2,4-dichlorophenol, were found to inhibit the rate of growth of adenocarcinoma H2712J and of spontaneous breast adenocarcinoma in mice. These agents do not affect the bone marrow in doses which are carcinostatic. Synthetic auxins and polychlorophenols, therefore, are a new family of compounds suitable for study in cancer chemotherapy.
Redefining Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Authors: Per Fink, Andreas Schröder
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Optimal Recall Rates Following Mammography—Reply
Authors: Rebecca Smith-Bindman, Karla Kerlikowske, Rachel Ballard-Barbash
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Impact of the 2014 Expert Panel Recommendations for Management of High Blood Pressure on Contemporary Cardiovascular Practice
Authors: William B. Borden, Thomas M. Maddox, Fengming Tang, John S. Rumsfeld, William J. Oetgen, J. Brendan Mullen, Sarah A. Spinler, Eric D. Peterson, Frederick A. Masoudi
Journal: Journal of the American College of Cardiology (2014)
The Eye and Systemic Disease.
Authors: Frederick A. Mausolf
Journal: Annals of Internal Medicine (1980)

This book is a practical guide to ambulatory management of HIV-infected patients. It also provides a survey of relevant clinical background information, such as testing methodology, management of life-threatening complications, and clinical manifestations of HIV infection. The most popular AIDS texts currently on the market all attempt a comprehensive discussion on the virological, immunological and clinical features of HIV infection but do not emphasize practical management issues confronted by the practitioner. Case studies illustrating the major points covered in the text are provided. The organization provides a logical sequence of topics for those who wish to review the entire book as well as a convenient breakdown for finding specific information.
Pseudocystic Condition of Lymph Nodes in C57BL Mice
Authors: G. Rudali, J. Reverdy, L. Chieco-Bianchi, N. Yourkovski
Journal: JNCI Journal of the National Cancer Institute (1960)

In a colony of a substrain of C57BL mice bred for 6 years, many cases of ectatic transformation of superficial lymph nodes were observed. The pseudocysts that developed in this way did not produce any alteration in the general state of health; their presence was compatible with long survival. Histogenetic study showed that the cysts always developed from the central sinuses and that their occurrence did not seem related to a change in the lymphatic flow through the efferent vessels. At the precystic stage, the lymph nodes exhibited a degenerative process of the reticular cells, especially in the hilar region; a marked rise in the number of mast cells which were more or less degranulated; and some megakaryocytes. The pseudocystic condition of nodes was more frequent in females than in males. Among 220 females, 40 (17%) had pseudocysts; among 154 males, only 9 (6%) had them. The average latency for both sexes was approximately 14 months. The injection of the cystic fluid into mice of other strains did not produce such ectatic changes. In newborn C57BL mice, it did not induce precocious appearance of cysts. The occurrence of the lesions did not seem related to senility.
Abstract 12067: Serum Immunoglobulin G4 Level is a Useful Marker for the Assessment of Low-Density Coronary Plaque
Authors: Aiko Sakamoto, Nobukazu Ishizaka, Jiro Ando, Masae Uehara, Ryozo Nagai, Issei Komuro
Journal: Circulation (2014)

Objective: Rupture of atherosclerotic coronary plaque is the most frequent cause of acute coronary syndrome. Although an immuno-inflammatory process is recognized to play a crucial role in the pathogenesis of atherosclerosis, it remains unclear whether immunoglobulin G4 (IgG4)-related immuno-inflammation is associated with coronary plaque vulnerability. The association between serum IgG4 levels and low-density plaque (LDP) was analyzed. Methods: We measured serum levels of IgG4 and high-sensitivity C-reactive protein (hsCRP) in 325 patients (193 males; mean age, 68.2 ± 10.8 years) who underwent 320-slice coronary computed tomography angiography (CCTA). The presence or absence of LDP was evaluated, and epicardial fat volume (EFV) was also calculated. Results: A total of 130 patients (40.0%) were judged to have LDP by CCTA. Serum levels of IgG4 and hsCRP were both significantly higher in patients with LDP than in those without (IgG4, 32.4 mg/dL [interquartile range, IR 18.6-81.2] vs. 24.0 mg/dL [IR 13.2-49.0], P=0.002; hsCRP, 0.10 mg/dL [IR 0.05-0.23] vs. 0.07 mg/dL [IR 0.03-0.15], P=0.008). The median of EFV was significantly greater in patients with LDP than in those without (112 mL [IR 78-148] vs. 94 mL [IR 74-127], P=0.011). EFV had a significant association with serum levels of IgG4 (R=0.117, P=0.035) and hsCRP (R=0.200, P&lt;0.001). In logistic regression analysis using age, gender, EFV, serum hsCRP levels, estimated glomerular filtration rate (eGFR), smoking, hypertension, dyslipidemia, and diabetes as covariates, the fourth quartile of IgG4 (≥56.7 mg/dL) was significantly associated with LDP with an odds ratio of 2.15 (95% confidence interval 1.07-4.34, P=0.032). Conclusions: Serum levels of IgG4 were significantly associated with LDP, and this relationship was, at least in part, independent of traditional cardiovascular risk factors and serum hsCRP levels. IgG4-related immuno-inflammation may affect coronary plaque vulnerability.
"Double depression": superimposition of acute depressive episodes on chronic depressive disorders
Authors: Martin B. Keller, Robert W. Shapiro
Journal: American Journal of Psychiatry (1982)

Although "double depression"--major depressive disorder superimposed on an underlying chronic depression--is a frequent phenomenon, the concept has not been well formulated clinically and has rarely been described in the research literature. The authors found that 1) 26% of l0l patients who met the criteria for major depressive disorder had an underlying chronic depressive disorder of at least 2 years' duration, 2) "recovery" rates for patients with superimposed depression differed greatly depending on whether recovery was defined as recovery from the major depressive disorder only or recovery from both disorders, and 3) patients with superimposed depression relapsed at a significantly higher rate immediately after recovery from the acute episode of depression than did patients without superimposed depression.
NIH Program to Fund Research on Molecular Changes Associated With Physical Activity
Authors: Julie Jacob
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Association of the Cyclin D1 A870G Polymorphism With Advanced Colorectal Cancer
Authors: Loïc Le Marchand
Journal: JAMA (2003)

ContextCyclin D1 (CCND1) is a key cell cycle regulatory protein, the overexpression of which is often found in human tumors and is associated with cell proliferation and poor prognosis. A common adenine-to-guanine substitution polymorphism (A870G) in the CCND1 gene results in an altered messenger RNA transcript and a longer-life protein, which are preferentially encoded by the A allele.ObjectiveTo test the overall and stage-specific associations of the CCND1 870A allele with colorectal cancer.Design, Setting, and ParticipantsA population-based case-control study conducted in the multiethnic population of Hawaii between January 1, 1994, and August 31, 1998, which included 504 patients with incident colorectal cancer and 624 population-based participants of Japanese, white, or Native Hawaiian origin. Participation rates were 58% for cases and 52% for controls.Main Outcome MeasurementEthnicity, gene-dosage effects, and stage (regional/distant) and subsite (colon vs rectal) of cancer.ResultsThe odds ratio (OR) for the CCND1 870 GA and AA genotypes compared with the GG genotype was 1.2 (95% confidence interval [CI], 0.9-1.7) and 1.5 (95% CI, 1.0-2.1), respectively (P = .03 for gene-dosage effect). These risk estimates were significantly greater for patients diagnosed at a regional or distant stage (GA vs GG: OR, 1.7; 95% CI, 1.1-2.5 and AA vs GG: OR, 1.9; 95% CI, 1.2-3.1; P = .008 for gene-dosage effect) compared with those estimates for patients diagnosed at an earlier stage (P = .048). In subset analyses, the association between the A allele and advanced colorectal cancer was statistically significant in white and Hawaiian participants but not in Japanese, and was stronger for rectal cancer.ConclusionThe CCND1 870A allele may be associated with colorectal cancer, and particularly with forms of the disease that result in severe morbidity and mortality.
Observations on a model of proliferative lung disease
Authors: B. Strauss, P. R. B. Caldwell, H. W. Fritts
Journal: Journal of Clinical Investigation (1970)

Intravenous injections of complete Freund's adjuvant, used by others to stimulate the reticuloendothelial system of small laboratory animals, produced granulomas resembling sarcoid in the lung of the dog. At the height of the disease, when granulomas occupied more than half of the alveolar tissues, transpulmonary arteriovenous (A-[unk]V) differences of lactate, pyruvate, and glucose were measured. When the diseased dogs breathed room air, the A-[unk]V differences of lactate and pyruvate were greater than normal; and when the dogs breathed an hypoxic mixture, the differences increased further. Hence the model affords the opportunity for studying the in vivo metabolism of diseased lungs. It may also prove useful for studying other aspects of granulomatous disease which cannot be easily approached in man.
Disruption of tubular Flcn expression as a mouse model for renal tumor induction
Authors: Jindong Chen, Dachuan Huang, Isabelle Rubera, Kunlhlko Futami, Pengfei Wang, Peter Zlckert, Sok-Kean Khoo, Karl Dykema, Ping Zhao, David Petillo, Brian Cao, Zhongfa Zhang, Shuhui Si, Susan R. Schoen, Ximing J. Yang, Ming Zhou, Guang-Qian Xiao, Guan Wu, Magnus Nordenskjöld, Michel Tauc, Bart O. Williams, Kyle A. Furge, Bin Tean Teh
Journal: Kidney International (2015)
"Cures" for Leukaemia
Authors: H K BOURNS, N G SANERKIN
Journal: BMJ (1964)

PointersTuberculosis Control: Dr. Wallace Fox, out- lining a realistic antituberculosis policy for developing countries, gives priority to a year's chemotherapy for each newly diagnosed active case.These countries should concentrate on " ambulatory domiciliary chemotherapy " (p.135).Eaton Agent Pneumonia: Serological studies in Finland suggest this organism was quite a com- mon cause of pneumonia in hospital (p.142).Actinomycosis: A study of the sensitivity of A. israelii to antibiotics.Benzylpenicillin is confirmed as the antibiotic of choice, but no evidence is found of strains varying in resis- tance (p. 145).Paratyphoid: Ampicillin and chloramphenicol have been compared in 145 cases of paratyphoid B. Ampicillin " can be looked upon as a useful alternative in the patient who has failed to respond to chloramphenicol " (p. 148).Leader at p. 132.Aversion Therapy: An apparatus giving electric shocks is claimed to have advantages over nausea-producing drugs (p.151).Suxamethonlum Apnoea: Investigation of families of five out of seven patients with hereditary atypical pseudocholinesterase. Patients, rela- tives, and G.P.s should be warned (p. 153).Abnormal Serum Lipids: Lowered by pro- longed oral nicotinic acid (p. 157).Plasma Amylase: Diagnostic value in separating acute pancreatitis from surgical abdominal emergencies (p.160).Encephalitis: Associated with lymphocytic choriomeningitis (p.162).Malignant Pericardial Effusion: Control of cardiac tamponade (p. 164).Fat-soluble Vitamins: Deficiency states, therapy, and toxic effects discussed in " To- day's Drugs " (p. 165).Rehabilitation of Injured: Place of industrial rehabilitation unit (p.173)." Deadly Cigarettes ": Leader at p. 133.Leukaemia: M. Naessens's serum (p. 175).Leader on this page.
Ganciclovir Intraocular Implant
Authors: Norman C. Charles, German C. Steiner
Journal: Ophthalmology (1996)

Background: Surgical implantation of the intraocular sustained-release ganciclovir device is a safe and effective treatment for cytomegalovirus (CMV) retinitis.Previous histopathologic studies on eyes containing such implants have been limited by the necessity of removing the device before processing.Microtome sectioning of hard plastics within paraffin-embedded blocks is infeasible, and the anatomic relations of implant to eye are destroyed.Methods: The authors studied four eyes from three patients who had undergone implant insertion.Globes with implants in place were fixed in neutral 10% formalin, embedded in methylmethacrylate, sectioned on a special microtome, and stained with hematoxylin-eosin.Results: After methacrylate embedding, the precise anatomic relations of the implant to the neighboring uveoscleral coats were preserved.In two eyes, the suture tab of the implant protruded through the sclera, exiting subconjunctivally.In two eyes, the implant was totally intravitreal.In all patients, the device was supported by fibrous tissue which emanated from a surgical coloboma of the pars plana ciliaris.Focal granulomatous inflammation adjoined suture and implant materials but no other inflammation or deleterious effects on the ocular structures were noted. Conclusion:This report is the first to document the intraocular histopathology of the ganciclovir implant.The subconjunctival location, enhancing the potential for endophthalmitis, may be avoided by trimming of the suture tab close to the anchoring suture and not tying it too tightly.Methylmethacrylate embedding is a useful technique for preserving the microanatomy of intraocular implants.
240. Immunogenicity of Dystrophins Delivered to Mice by Gutted Adenoviral Vectors
Authors: Jie Mi, Leonard Leuse, Jeannine Scott, Shannon Barker, Shanna Sawatzki, Dennis Hartigan-O'Connor, Jeffrey S. Chamberlain
Journal: Molecular Therapy (2004)

Duchenne muscular dystrophy (DMD) is an X-linked recessive genetic disorder resulting from mutations in the dystrophin gene. Delivery of a therapeutic dystrophin gene back into the diseased muscle has been suggested as a means of gene therapy for DMD. Previous work in this lab has demonstrated that using a gutted adenovirus vector (gAd), a full-length dystrophin cDNA expression cassette can be delivered into muscles of the mdx (dystrophin-deficient) mouse, resulting in efficient transduction of myofibers with dystrophin. A long-term follow-up study has revealed that the gAd delivered, muscle-specific promoter-driven, gene expression could be sustained for up to six months in adult mdx mice when delivering mouse dystrophin or mouse utrophin. In contrast, delivery of full-length human dystrophin (hDys) using gAd vectors resulted in a slow loss of gene expression over the 6-month window. Furthermore, an increase in the number of infiltrating CD4+ and CD8+ T-cells was observed in muscles injected with the human, but not the mouse, dystrophin-expressing gAd vectors. These results suggest that a host immune response has been elicited, albeit possibly mild, against the hDys-expressing muscle fibers. Despite this slow loss of hDys expression, a number of small caliber, regenerating myofibers were observed at the 6 month time point that expressed the human protein, suggesting that gAd vectors can be retained for many months in satellite cells even in the presence of an immune response against dystrophin expression in myofibers.
Abstract 14664: SIRT3 Protects Cardiomyocytes From Doxorubicin-induced Mitochondrial Damage and Cell-death by Activating Opa1
Authors: Sadhana Samant, Vinodkumar Pillai, Don Wolfgeher, Mahesh Gupta
Journal: Circulation (2014)

Introduction: The anti-cancer drug therapy with doxorubicin (Dox) is known to produce cardiomyopathy associated with fragmentation of mitochondria and excess production of reactive oxygen species (ROS). Sirtuin3 (SIRT3), a mitochondrial deacetylase regulates many mitochondrial functions including energy production, ROS synthesis and cell-death. A role of SIRT3 in regulating the aging process and aging-associated diseases like heart failure, cancer and diabetes has been also documented. This study was undertaken to investigate whether SIRT3 can protect cardiomyocytes from Dox-induced mitochondrial damage and cell-death. Methods and Results: Neonatal rat cardiomyocytes were over expressed with a vector synthesizing SIRT3 or a mock vector. Cells were treated with Dox (100nM) for 72 hours and cell-death was analyzed by measuring TUNEL-positive nuclei, ROS synthesis and expression of apoptotic markers by the western blotting. There was marked reduction of TUNEL-positive nuclei, ROS levels and expression of apoptotic markers such as Bax, Bim and FasL in SIRT3 over expressing cells, compared to control cells received the mock vector. Confocal imaging of myocytes revealed that Dox-treatment caused swelling and fragmentation of mitochondria in control cells, but not in cells over expressed with SIRT3. To understand the mechanism involved in SIRT3-mediated protection of mitochondria we analyzed acetylation of proteins involved in regulating mitochondrial fusion-fission dynamics. We found that OPA1 (optic atrophy-1), an essential inner membrane fusion protein, was hyper-acetylated in Dox-treated cells, leading to its reduced GTPase activity. SIRT3 was capable of deacetylating and augmenting GTPase activity of OPA1 both in vitro and in vivo assay conditions. Furthermore, by studying OPA1 null cells we found that it is necessary for SIRT3-mediated protection of cardiomyocytes from mitochondrial damage and cell-death. Conclusions: These results indicated that SIRT3-dependent activation of OPA1 contributes to preservation of mitochondrial population and protection of cardiomyocytes from Dox-mediated cell-death. We believe that SIRT3 could be utilized as a therapeutic target for treatment of Dox-induced cardiomyopathy of the heart.
Effect of Certolizumab Pegol Over Ninety‐Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial
Authors: J. Sieper, R. Landewé, M. Rudwaleit, D. van der Heijde, M. Dougados, P. J. Mease, J. Braun, A. Deodhar, A. Kivitz, J. Walsh, B. Hoepken, T. Nurminen, W. P. Maksymowych
Journal: Arthritis & Rheumatology (2014)

Objective Previous reports of the RAPID‐axSpA trial (NCT01087762) described the efficacy and safety of certolizumab pegol (CZP) over 24 weeks in patients with axial spondyloarthritis (SpA), including ankylosing spondylitis (AS) and nonradiographic axial SpA. We report efficacy and safety data up to week 96 of the study. Methods The RAPID‐axSpA trial is double‐blind and placebo‐controlled to week 24, dose‐blind to week 48, and open‐label to week 204. Outcome variables included Assessment of SpondyloArthritis international Society criteria for 20% and 40% improvement in disease activity (ASAS20/40), ASAS partial remission responses (analyzed by nonresponder imputation), AS Disease Activity Score (ASDAS), ASDAS inactive disease, ASDAS major improvement, Bath AS Disease Activity Index (BASDAI), Bath AS Functional Index (BASFI), and Bath AS Metrology Index (BASMI) linear score (analyzed by the last observation carried forward method). Safety data were collected for patients treated with ≥1 dose of CZP. Results Of the 325 patients who were randomized, 218 received CZP from week 0. Of these, 93% completed week 24, 88% completed week 48, and 80% completed week 96. Improvements in ASAS responses were maintained to week 96 (for ASAS20, 67.4%, 72.0%, and 62.8% at weeks 24, 48, and 96, respectively), as well as improvements in ASDAS, BASDAI (mean score 3.3, 3.1, and 3.0 at weeks 24, 48, and 96, respectively), BASFI, and BASMI linear score. Comparable improvements were observed with both dosing regimens (200 mg every 2 weeks or 400 mg every 4 weeks) and in patients with AS and those with nonradiographic axial SpA. In the safety set, adverse events occurred in 279 patients (88.6%) and serious adverse events in 41 (13.0%). No deaths or malignancies were reported. Conclusion Clinical improvements to week 24 in both CZP dosing regimens were sustained to week 96. Similar sustained improvements were observed in AS and nonradiographic axial SpA subpopulations. The safety profile was consistent with previous reports from RAPID‐axSpA, with no new safety signals observed with longer exposure.